Abstract
Multiple myeloma is a severe malignance caused by damaged B cells from bone marrow plasma cells. Multiple treatments have been introduced to release and treat such a disease, but in general, high rate and severity of adverse events and relatively unideal efficacies of those existing treatments necessitate a new therapy achieving a better curative effect. Thus, CARVYKTI, a CAR-T therapy, has been developed for treat patients with multiple myeloma and who have already received several other treatments. By having genetically modified T cells, damaged cancer-causing B cells are targeted and vanished specifically. Recently, the FDA has officially approved CARVYKTI as a treatment for refractory multiple myeloma, and the basic pharmacology and the phase1b-2 clinical trial are summarized in this paper.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
